labour'. The Economist gave Leroy Hood an award this year for his invention of the fluorescence sequencing machine, and co-authorship of the 1996 paper 'A new strategy for genomic sequencing'. With another award going to Stephen Fodor for his Affymax gene chip work, it is clear that The Economist thinks that these bioinformatics-dependent technologies matter in the real world.
Even introductory courses on retailing economics should stress that the customer is always right. Ultimately, Cereon Genomics was closed down despite its successful work studying natural disease resistance in plants, hard labour from the staff and all the financial clarity of its leaders. The closure was due more to anxieties over an EU moratorium on new genetically modified (GM) crop approvals 10 and consumer perceptions that even properly tested GM food might somehow still be especially dangerous. It is clear that supermarket shoppers are ignorant of the thousands of years of genetic modification and selection that has traditionally fed us all: polyploidy is common 11 in commercial crops -wild wheat varieties can be tetraploid or hexaploid, 12,13 bananas are triploid 14 and the apple 15 (that keeps the doctor away) is actually a genetic fusion of eight pairs of chromosomes from a plum member of the rose family, and nine pairs from meadowsweet! For more information on crops genetics maps and bioinformatics see Dicks et al. 16 or the UK CropNet web site. 17 The most pointed advice that I have heard on bioinformatics and economics was offered by my boss at Cereon: 'Never work for a pure bioinformatics company!' So what's next? Sydney Brenner interested me and many others in all aspects of partially sequenced cDNAs (before the term 'Expressed Sequence Tag' or EST was invented) but the next boom may be harder to predict. Looking for other guidance, perhaps, Adam Smith's invisible hand 18 is pointing in the same direction as Willie Sutton's first principle of economics: 'I rob banks because that is where the money is' and it has long been obvious how bioinformatics can help increase the efficiency of the already wealthy pharmaceutical companies. However, following the money has two different limitations: firstly, much of the best research is precompetitive and can be done on a shoestring by academics, and secondly, there is a limit to how much even Americans are prepared to spend on drugs.
Clear examples of excellent precompetitive academic work include the NCBI's Entrez system 19 and the joint EBI/Sanger Institute's ENSEMBL databases. 20 The NCBI is generously contracted to share with everyone worldwide and without charge its great work linking DNA, proteins, publications and disease databases. Similarly, the ENSEMBL project has made its highly respected derived database of the finished genomes available to everyone but also enabled the databases to be mirrored (not just as flat files) inside each individual pharmaceutical company, saving them all the enormous effort of duplicating ENSEMBL's calculations and expert editing.
President Bush recently announced 21 a proposed change in the law to limit how often pharmaceuticals companies can extend their patents on lucrative drugs to allow cheaper generic drugs (average US$17 per prescription) to replace branded drugs (average US$72 per prescription). Pharmaceutical companies typically estimate a drug's worth by looking at its market in the USA which is bigger and pays more for the same product than do other economies, even Europe. Both the total GDP of the USA and the proportion spent on healthcare have been growing since 1945 and currently exceed 15 per cent, but there must be some limit even here. The market is finite and, ultimately, everyone will still die, just like before, so it makes sense to leave some money for other purposes, and ration healthcare. For now, the money is flowing through the pharmaceutical companies, and the economics suggests that they should be the most valuable place, in every sense, to be a bioinformatician.
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